Description

While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine

While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine combination of a poxvirus and protein are needed. With this aim, in this investigation we have generated derivatives of the candidate vaccinia virus vaccine vector NYVAC with potentially improved functions.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2011-11-09
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1371/journal.pone.0025674
    • Identifier Type
      International standard serial number
      Identifier Value
      1045-3830
    • Identifier Type
      International standard serial number
      Identifier Value
      1939-1560

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Kibler, K. V., Gomez, C. E., Perdiguero, B., Wong, S., Huynh, T., Holechek, S., . . . Esteban, M. (2011). Improved NYVAC-Based Vaccine Vectors. PLoS ONE, 6(11). doi:10.1371/journal.pone.0025674

    Machine-readable links